Search Site

Search form

Current Press Releases

All Releases
View Summary Vertex to Present at Upcoming Investor Conferences
Feb 9, 2016
PDF 8.1 KB
View Summary Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations
Feb 5, 2016
PDF 16.8 KB
View Summary Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
Jan 27, 2016
PDF 52.2 KB
View Summary Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jan 26, 2016
PDF 18.4 KB
View Summary Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases
Jan 10, 2016
PDF 39.1 KB
View Summary Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results
Jan 5, 2016
PDF 8.2 KB
Showing 1-6 of 6 Page: 1